Alnylam Pharmaceuticals and Arrowhead Research Corporation Form Collaboration and Licensing Agreement

CAMBRIDGE, Mass. & PASADENA, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Arrowhead Research Corporation, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity, announced today that they have entered into a collaboration and joint licensing agreement.

Back to news